SEARCH

SEARCH BY CITATION

References

  • Arboix, M., O. G. Paz, T. Colombo & M. D'Incalci: Multidrug resistance-reverting agents increase vinblastine distribution in normal tissue expressing the P-glycoprotein but not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Therap. 1997, 281, 12261230.
  • Baldessarini, R. J.: Drugs and the treatment of psychiatric disorders: Psychosis and anxiety. In: Goodman & Gilmann, The pharmacological basis of therapeutics 9th ed., McGraw-Hill, New York, 1996, pp. 399430.
  • Bellamy, W. T.: P-glycoprotein and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 161183.
  • Bloom, F. E.: Neurotransmission and the central nervous system. In: Goodman & Gilmann, The Pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill, New York, 1996, pp. 267293.
  • Childs, S. & V Ling: The MDR Superfamily of genes and its biological implications. Important. Adv. Oncol. 1994, 2136.
  • Chiu, S.-H. L., S. E. Sestokas & R. Taub: Application of two-dimensional high-performance liquid chromatography in metabolism studies of ivermectin. J. Chromatogr. 1988, 433, 217224.
  • Colombo, T., M. Zucchetti & M. D'Incalci: Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp. Therap. 1994, 269, 2237.
  • Cordon-Cardo, C., J. P. O'Brien, D. Casals, L. Rittman-Grauer, J. L. Biedler, M. R. Melamed & J. R. Bertino: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. 1989, 86, 695698.
  • Cordon-Cardo, C., J. P. O'Brien, J. Boccia, D. Casals, J. R. Bertino & M. R. Melamed: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990, 38, 12771287.
  • Dickinson, CM.: Improved high-performance liquid chromatography method for quantification of ivermectin in whole blood, serum or muscle tissue. J. Chromatogr. 1990, 528, 250257.
  • Didier, A. D. & F. Loor: Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int. J. Cancer 1995, 63, 263267.
  • Fahr, A.: Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 1993, 24, 472495.
  • Fisher, M. H. & H. Mrozik: The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32, 537553.
  • Ford, J. M. & W. N. Hait: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155199.
  • Gottesman, M. M. & I. Pastan: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385427.
  • Juliano, R. L. & V. A. Ling: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta 1976, 455, 152162.
  • Klotz, U., J. E. Ogbuokiri & P. O. Okonkwo: Ivermectin binds avidly to plasma proteins. Eur. J. Pharmacol. 1990, 39, 607608.
  • Martina, M., J. W. Mozrzymas, H. W. G. M. Boddeke & E. Cherubini: The calcineurin inhibitor cyclosporin A-cyclophilin A complex reduces desensitization of GABAA-mediated responses in acutely dissociated rat hippocampal neurons. Neurosci. Lett. 1996, 215, 9598.
  • Pouliot, J.-F, F. L'Heureux, Z. Liu, R. K. Prichard & E. Georges: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem. Pharmacol. 1997, 53, 1725.
  • Rumjanek, V. M., L. A. Smith & J. Morley: Cyclosporin A: A pre-recruitment action in the cutaneous response? Immunol. Lett. 1985, 6, 6972.
  • Sakata, A., I. Tamai, K. Kouichi, Y. Deguchi, T Ohnishi, A. Saheki & A. Tsuji: In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 1994, 48, 19891992.
  • Schinkel, A. H., J. J. M. Smit, O. van Tellinger, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. A. M. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. R. J. te Riele, A. J. Berns & P. Borst: Disruption of the mouse mdr la P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to an increased sensitivity to drugs. Cell 1994, 77, 491502.
  • Schinkel, A. H., E. Wagenaar, L. van Deemter, C. A. A. M. Mol & P. Borst: Absence of the mdr la P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 1995, 96, 16981705.
  • van Asperen, J., U. Mayer, O. van Tellingen & J. H. Beijnen: The functional role of P-glycoprotein in the blood-brain-barrier. J. Pharm. Sci. 1997, 86, 881884.
  • Wang, Q., H. Yang, D. W. Miller & W. F. Elmquist: Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of Rhodamine-123 to the brain: An in vivo microdialysis study in freely moving rats. Bioch. Biophys. Res. Commun. 1995, 211, 719726.
  • Yang, J. & C. F. Zorumski: Trifluoperazine blocks GABA-gated chloride currents in cultures chick spinal neurons. J. Neurophysiol. 1989, 61, 363373.
  • Zorumski, C. F. & J. Yang: Non-competitive inhibition of GABA currents by phenothiazines in cultured chick spinal cord and rat hippocampal neurons. Neurosci. Lett., 1988, 92, 8691.